Association of MSS/MSI-RNF43 molecular subtypes and clinical outcome of metastatic BRAF-V600E colorectal cancer patients treated with anti-BRAF/EGFR ± combinatorial therapies

被引：0
|
作者：
Elez, E. [1 ]
Ros, J. [2 ]
Randon, G. [3 ]
Lonardi, S. [4 ]
Cremolini, C. [5 ]
Pietrantonio, F.
Tabernero, J. [1 ,6 ]
Toledo, R. [1 ]
机构：
[1] Vall dHebron Inst Oncol, Barcelona, Spain
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain
[3] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[4] Veneto Inst Oncol IRCCS, Med Oncol, Padua, Italy
[5] Univ Pisa, Azienda Osped Univ Pisana, Unit Med Oncol, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[6] Vall dHebron Univ Hosp, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.04.449
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-8
引用
收藏
页码：S382 / S382
页数：1
相关论文
共 50 条
  • [1] RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer
    Elez, Elena
    Ros, Javier
    Fernandez, Jose
    Villacampa, Guillermo
    Moreno-Cardenas, Ana Belen
    Arenillas, Carlota
    Bernatowicz, Kinga
    Comas, Raquel
    Li, Shanshan
    Kodack, David Philip
    Fasani, Roberta
    Garcia, Ariadna
    Gonzalo-Ruiz, Javier
    Piris-Gimenez, Alejandro
    Nuciforo, Paolo
    Kerr, Grainne
    Intini, Rossana
    Montagna, Aldo
    Germani, Marco Maria
    Randon, Giovanni
    Vivancos, Ana
    Smits, Ron
    Graus, Diana
    Perez-Lopez, Raquel
    Cremolini, Chiara
    Lonardi, Sara
    Pietrantonio, Filippo
    Dienstmann, Rodrigo
    Tabernero, Josep
    Toledo, Rodrigo A.
    NATURE MEDICINE, 2022, 28 (10) : 2162 - +
  • [2] RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer
    Elena Elez
    Javier Ros
    Jose Fernández
    Guillermo Villacampa
    Ana Belén Moreno-Cárdenas
    Carlota Arenillas
    Kinga Bernatowicz
    Raquel Comas
    Shanshan Li
    David Philip Kodack
    Roberta Fasani
    Ariadna Garcia
    Javier Gonzalo-Ruiz
    Alejandro Piris-Gimenez
    Paolo Nuciforo
    Grainne Kerr
    Rossana Intini
    Aldo Montagna
    Marco Maria Germani
    Giovanni Randon
    Ana Vivancos
    Ron Smits
    Diana Graus
    Raquel Perez-Lopez
    Chiara Cremolini
    Sara Lonardi
    Filippo Pietrantonio
    Rodrigo Dienstmann
    Josep Tabernero
    Rodrigo A. Toledo
    Nature Medicine, 2022, 28 : 2162 - 2170
  • [3] Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments
    Ros, J.
    Matito, J.
    Villacampa, G.
    Comas, R.
    Garcia, A.
    Martini, G.
    Baraibar, I.
    Saoudi, N.
    Salva, F.
    Martin, A.
    Antista, M.
    Toledo, R.
    Martinelli, E.
    Pietrantonio, F.
    Boccaccino, A.
    Cremolini, C.
    Dientsmann, R.
    Tabernero, J.
    Vivancos, A.
    Elez, E.
    ANNALS OF ONCOLOGY, 2023, 34 (06) : 543 - 552
  • [4] Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
    Xu, Ting
    Wang, Xicheng
    Wang, Zhenghang
    Deng, Ting
    Qi, Changsong
    Liu, Dan
    Li, Yanyan
    Ji, Congcong
    Li, Jian
    Shen, Lin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [5] Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations
    Ros Montana, F. J.
    Navarro, V.
    Comas, R.
    Landolfi, S.
    Ramirez, L.
    Palmer, H. G.
    Garcia Rodriguez, A.
    Saoudi Gonzalez, N.
    Baraibar Argota, I.
    Rodriguez Castells, M.
    Salva Ballabrera, F.
    Tabernero, J.
    Elez Fernandez, M. E.
    ANNALS OF ONCOLOGY, 2023, 34 : S447 - S447
  • [6] Response to BRAF inhibitors combined with anti-EGFR after previous anti-EGFR exposure for BRAF V600E mutant metastatic colorectal cancer patients
    Hafliger, E.
    Boccaccino, A.
    El-Khoury, R.
    Perret, A.
    Pietrantonio, F.
    Pilla, L.
    Lecomte, T.
    Scartozzi, M.
    Soularue, E.
    Salvatore, L.
    Bourgeois, V.
    Salati, M.
    Vaillant, J. N.
    Gallois, C.
    Lonardi, S.
    Cremolini, C.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S554 - S554
  • [7] Molecular characterization of microsatellite stable (MSS) colorectal cancer (CRC) patients with a BRAF V600E mutation
    van der Pol, Ymke
    Yilma, Binyam
    Morris, Van K.
    Chao, Calvin
    Harris, Michelle
    Guinney, Justin
    Kopetz, Scott
    CANCER RESEARCH, 2024, 84 (06)
  • [8] Predictive impact of RNF43 mutation (mut) in patients (pts) with pMMR/MSS BRAF V600E mutated metastatic colorectal cancer (mCRC) treated with target therapy (TT) or chemotherapy (CT)
    Germani, Marco Maria
    Moretto, Roberto
    Montana, Javier Ros
    Intini, Rossana
    Ghelardi, Filippo
    Vetere, Guglielmo
    Toledo, Rodrigo De Almeida
    Bergamo, Francesca
    Randon, Giovanni
    Elez, Elena
    Lonardi, Sara
    Oldani, Simone
    Giordano, Mirella
    Rossini, Daniele
    Bravo, Walter Ferrari
    Ricagno, Gianmarco
    Ugolini, Paola Vignali Clara
    Fontanini, Gabriella
    Cremolini, Chiara
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Real-world evaluation of clinical outcomes and long-term survivors in patients with BRAF-V600E metastatic colorectal cancer
    Phillips, William
    Alrehaili, Mohammad
    Marginean, Horia
    Asmis, Tim
    Vickers, Michael M.
    Lo, Bryan
    Goodwin, Rachel Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 166 - 166
  • [10] Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer
    Yaeger, Rona
    Kotani, Daisuke
    Mondaca, Sebastian
    Parikh, Aparna R.
    Bando, Hideaki
    Van Seventer, Emily E.
    Taniguchi, Hiroya
    Zhao, HuiYong
    Thant, Claire N.
    de Stanchina, Elisa
    Rosen, Neal
    Corcoran, Ryan B.
    Yoshino, Takayuki
    Yao, Zhan
    Ebi, Hiromichi
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 7089 - 7097
12345